India Says Homegrown MRNA COVID-19 Shot Safe In Early Trial

Sinhaajay397@gmail.c11 Oct, 2021News

Indian pharmaceutical firm Gennova Biopharmaceuticals’ COVID-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said on Tuesday. Government authorities have also approved further studies to test the vaccine’s efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India.